Buscar en
Farmacia Hospitalaria
Toda la web
Inicio Farmacia Hospitalaria Línea estratégica 2, Medicina basada en la evidencia
Información de la revista
Vol. 35. Núm. S1.
Jornada Post Midyear 2009. “Apostando por el 2020”
Páginas 21-27 (Febrero 2011)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 35. Núm. S1.
Jornada Post Midyear 2009. “Apostando por el 2020”
Páginas 21-27 (Febrero 2011)
Acceso a texto completo
Línea estratégica 2, Medicina basada en la evidencia
Visitas
...
A.. Arangurena
a Servicio de Farmacia, Hospital Universitario La Princesa, Madrid, España
Información del artículo
El Texto completo está disponible en PDF
Bibliograf??a
[1]
Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2008; 133(Suppl 6):381S-453S. 8th ed
[2]
American Academy of Orthopaedic Surgeons. Clinical guideline on pulmonary embolism in patients undergoing total hip or knee arthroplasty [citado en mayo de 2007]. Disponible en: http://wwwaaosorg/Research/guidelines/PE_guidelinepdf.
[3]
American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007; 25:5490-505.
[4]
Hospitals’ compliance with prophylaxis guidelines for venous thromboembolism. Am J Health Syst Pharm. 2007; 64:69-76.
[5]
Thromboprophylaxis rates in US medical centers: success or failure?. J Thromb Haemost. 2007; 5:1610-6.
[6]
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007; 370:949-56.
[7]
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007; 5:2178-85.
[8]
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009; 24:1-9.
[9]
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008; 358:2765-75.
[10]
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008; 372:31-9.
[11]
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008; 358:2776-86.
[12]
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009; 373:1673-80.
[13]
Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009; 361:594-604.
[14]
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361:1139-51.
[15]
Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361:2342-52.
[16]
Human albumin administration in critically ill patients: systematic review of randomised controlled, trials. Cochrane Injuries Group Albumin Reviewers. BMJ. 1998; 317:235-40.
[17]
Crystalloids vs. colloids in fluid resuscitation: a systematic review. Crit Care Med. 1999; 27:200-10.
[18]
Patient survival after human albumin administration. A meta-analysis of randomized, controlled trials. Ann Intern Med. 2001; 135:149-64.
[19]
Morbidity in hospitalized patients receiving human albumin: a meta-analysis of randomized, controlled trials. Crit Care Med. 2004; 32:2029-38.
[20]
A paradigm for consensus. The University Hospital Consortium guidelines for the use of albumin, nonprotein colloid, and crystalloid solutions. Arch Intern Med. 1995; 155:373-9.
[21]
Evidence-based colloid use in the critically ill: American Thoracic Society Consensus Statement. Am J Respir Crit Care Med. 2004; 170:1247-59.
[22]
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008; 36:296-327.
[23]
Fluid resuscitation with colloid or crystalloid solutions in critically ill patients: a systematic review of randomised trials. BMJ. 1998; 316:961-4.
[24]
7.5% sodium chloride/dextran for resuscitation of trauma patients undergoing helicopter transport. Arch Surg. 1991; 126:1065-72.
[25]
Prehospital resuscitation of hypotensive trauma patients with 7.5% NaCl versus 7.5% NaCl with added dextran: a controlled trial [discussion 32–3]. J Trauma. 1993; 34:622-32.
[26]
Hypertonic solutions in the treatment of hypovolemic shock: a prospective, randomized study in patients admitted to the emergency room. Surgery. 1992; 111:380-5.
[27]
Prognostic factors to predict outcome following the administration of hypertonic/hyperoncotic solution in hypovolemic patients. Shock. 1997; 7:79-83.
[28]
Prehospital hypertonic saline/dextran infusion for post-traumatic hypotension. The U.S.A. Multicenter Trial. Ann Surg. 1991; 213:482-91.
[29]
Efficacy of hypertonic 7.5% saline and 6% dextran-70 in treating trauma: a meta-analysis of controlled clinical studies. Surgery. 1997; 122:609-16.
[30]
Efficacy of hypertonic saline dextran (HSD) in patients with traumatic hypotension: meta-analysis of individual patient data. Acta Anaesthesiol Scand Suppl. 1997; 110:77-9.
[31]
Individual patient cohort analysis of the efficacy of hypertonic saline/dextran in patients with traumatic brain injury and hypotension. J Trauma. 1997; 42(Suppl 5):S61-5.
[32]
The use of hypertonic saline in the treatment of traumatic brain injury. J Trauma. 2001; 50:367-83.
[33]
Prehospital hypertonic saline resuscitation of patients with hypotension and severe traumatic brain injury: a randomized controlled trial. JAMA. 2004; 291:1350-7.
[34]
Hypertonic resuscitation of hypovolemic shock after blunt trauma: a randomized controlled trial [discussion 49]. Arch Surg. 2008; 143:139-48.
[35]
Impact of hemorrhage on trauma outcome: an overview of epidemiology, clinical presentations, and therapeutic considerations. J Trauma. 2006; 60(Suppl 6):S3-S11.
[36]
Strategies for transfusion therapy. Best Pract Res Clin Anaesthesiol. 2004; 18:661-73.
[37]
Massive transfusion practices around the globe and a suggestion for a common massive transfusion protocol. J Trauma. 2006; 60(Suppl 6):S91-6.
[38]
Factor VIIa (recombinant) for acute traumatic hemorrhage. Am J Health Syst Pharm. 2008; 65:1616-23.
[39]
Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials [discussion 8]. J Trauma. 2005; 59:8-15. discussion-8
[40]
The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma. 2003; 55:886-91.
[41]
Pharmacokinetics of recombinant activated factor VII in trauma patients with severe bleeding. Crit Care. 2006; 10:R104.
[42]
How accurate is weight estimation in the emergency department?. Emerg Med Australas. 2005; 17:113-6.
[43]
Dosing and monitoring NovoSeven treatment. Haemostasis. 1996; 26(Suppl 1):102-8.
[44]
Management of bleeding following major trauma: a European guideline. Crit Care. 2007; 11:R17.
[45]
Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force. J Thromb Haemost. 2005; 3:640-8.
[46]
Consensus recommendations for the off-label use of recombinant human factor VIIa (NovoSeven®) therapy. Pharmacy & Therapeutics. 2005; 30:644-58.
Opciones de artículo
Herramientas
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos